Compare ARDX & AMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | AMRC |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2014 | 2010 |
| Metric | ARDX | AMRC |
|---|---|---|
| Price | $5.69 | $26.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $15.14 | ★ $39.38 |
| AVG Volume (30 Days) | ★ 3.7M | 424.8K |
| Earning Date | 05-12-2026 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | $2,607,000.00 | ★ $1,769,928,000.00 |
| Revenue This Year | $38.22 | $10.29 |
| Revenue Next Year | $33.85 | $10.42 |
| P/E Ratio | ★ N/A | $52.69 |
| Revenue Growth | N/A | ★ 28.76 |
| 52 Week Low | $3.50 | $8.49 |
| 52 Week High | $8.40 | $44.93 |
| Indicator | ARDX | AMRC |
|---|---|---|
| Relative Strength Index (RSI) | 34.97 | 38.54 |
| Support Level | $5.49 | $26.29 |
| Resistance Level | $6.23 | $31.12 |
| Average True Range (ATR) | 0.31 | 1.74 |
| MACD | -0.06 | -0.55 |
| Stochastic Oscillator | 11.79 | 19.85 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.